Study of factors influencing the in vivo methylation of inorganic arsenic in rats.
Previous studies have shown that several factors may influence the methylation of inorganic arsenic by rat liver in vitro (Buchet and Lauwerys, 1985). The present study attempts to assess the relevance of these observations in vivo. Like man, rat inactivates inorganic arsenic by methylation to monomethylarsonic (MMA) and dimethylarsinic (DMA) acids which are excreted in urine along with unchanged inorganic arsenic (Asi). The administration of S-adenosylmethionine alone or in association with reduced (GSH) or oxidized glutathione or acetylcysteine and the increase of hepatic GSH level by butylated hydroxytoluene pretreatment do not stimulate the urinary excretion of the methylated arsenic metabolites following a challenge dose of inorganic arsenic. Conversely a reduction of the hepatic GSH level by phorone pretreatment greatly modifies the metabolism of inorganic arsenic in vivo. A reduction exceeding 90% of the control value leads to a decreased urinary excretion of MMA and DMA and an increased urinary excretion of inorganic arsenic. This is also associated with an increased accumulation of inorganic arsenic in the liver. This suggests that a drastic reduction of GSH level in liver not only impairs the methylation of inorganic arsenic but also impairs its biliary excretion. When GSH depletion is less severe, the total amount of arsenic excreted in urine after a challenge dose of NaAsO2 is not significantly different from that found in unpretreated animals but the proportion of the three metabolic forms is different: MMA is reduced whereas Asi and DMA tend to increase. These changes resemble those found in patients with liver insufficiency (J.P. Buchet, A. Geubel, S. Pauwels, P. Mahieu, and R. Lauwerys (1984). The influence of liver disease on the methylation of arsenite in humans. Arch. Toxicol. 55, 151-154). Long-term pretreatment of rats with CCl4 slightly reduces the amount of MMA and DMA excreted in urine following a challenge dose of inorganic arsenic. This effect may result from a reduction of GSH transferase activity by CCl4. This study demonstrates the important role of liver GSH in the metabolism of inorganic arsenic in vivo.
Buchet
J P
JP
Industrial Toxicology and Occupational Health Unit, University of Louvain, Brussels, Belgium.
Lauwerys
R
R
D000818:Animals; D001151:Arsenic / Q000378:metabolism* / Q000652:urine; D001152:Arsenicals / Q000378:metabolism / Q000652:urine; D002101:Cacodylic Acid / Q000378:metabolism / Q000652:urine; D002251:Carbon Tetrachloride / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005978:Glutathione / Q000378:metabolism; D007659:Ketones / Q000494:pharmacology; D008099:Liver / Q000378:metabolism*; D008745:Methylation; D010084:Oxidation-Reduction; D051381:Rats; D011919:Rats, Inbred Strains; D012643:Selenium / Q000494:pharmacology
D001152:Arsenicals; D007659:Ketones; C018637:phorone; D002101:Cacodylic Acid; D002251:Carbon Tetrachloride; D005978:Glutathione; D012643:Selenium; C020300:monomethylarsonic acid; D001151:Arsenic